

## NEW HANOVER REGIONAL MEDICAL CENTER

Data from: January 2011 to December 2016

### Percent Susceptible

(A blank box can mean that drug has not been tested or is inappropriate for that bacteria)

Antibiotics	M. tuberculosis (45)	M. avium intracellulare complex (91)
Ethambutol <sup>d</sup>	100	
Isoniazid	75↓	
Pyrazinamide	96↑	
Rifampin <sup>d</sup>	100	
Clarithromycin <sup>a,c</sup>		100
Clofazimine		88↓
Moxifloxacin <sup>a,b</sup>		47↑

**In vitro susceptibility determined by microbroth dilution at North Carolina State Laboratory, National Jewish Center for Immunology and Respiratory Medicine, Denver Colorado, or LabCorp Reference Laboratory, NC. Results are percent susceptible.**

**Notes:**

- a) Recommended reported for MAC by CLSI M24-A2 January 13
- b) The breakpoints for these agents are considered tentative and may be revised as more data is accumulated.
- c) Clarithromycin is the class drug for macrolides, and is the only drug tested for this class.
- d) Ethambutol, rifampin, rifabutin, streptomycin, and amikacin are useful clinically for MAC, breakpoints are not established. Contact ID for consult.
- ↑ Susceptibility has gone up from last year
- ↓ Suceptibility has gone down from last year